Hypertensive intracerebral hemorrhage
Conditions
Interventions
Cattle encephalon glycoside and ignotin Cattle encephalon glycoside and ignotin (CEGI) injection:250ml, intravenous drip, q.d.
Placebo:250ml, intravenous drip, q.d.
Sponsors
The First Affiliated Hospital of PLA Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Individuals aged 18-75 years; 2. Newly diagnosed, untreated hypertensive intracerebral hemorrhage, bleeding position and volume were Basal ganglia and 25-50ml diagnosed by Head CT. The hemorrhage did not break into lateral ventricle; 3. Obvious neurological dysfunction after onset with no signs of cerebral hernia, GCS evaluation between 5-14, or NIHSS above 6, non-surgical treatment; 4. Recruit patients within 72 hours after onset, and CT examination shows no hematomas expansion in 6 hours and above after diagnostic CT (hematoma=5ml); 5. All patients gave written informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with cerebral hemorrhage caused by cerebral aneurysm, brain tumor, brain trauma, cerebral parasitic disease, cerebrovascular malformation, moyamoya disease, cerebral arteritis, hematological diseases, metabolic disorders; 2. Patients whose hematoma is unstable or progress into intracranial hypertension syndrome; 3. Ever diagnosed with subarachnoid hemorrhage and ischemic cerebral infarction; 4. Ever received Anticoagulants or Antiplatelet drug treatment; 5. Abnormal coagulation function (platelet count 1.4); 6. Patients who need operation treatment (including external ventricular drainage); 7. Patients who may suffer from mental or physical diseases that interfere treatment evaluation; 8. Homocysteine determination value higher than 15µmol/L when admitted into hospital; 9. Patients who have serious diseases in heart, lung, liver, kidney, endocrine or hemopoietic system; 10. Allergic to protein or treatment medicine; 11. Drug or alcohol addiction; 12. Prospective pregnant women, women of childbearing age positive in pregnancy test or lactating women; 13. participated in other clinical trials within 3 months; k) patients considered not suitable for clinical trials by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glasgow Outcome Scale - Extended (GOS-E); | — |
Secondary
| Measure | Time frame |
|---|---|
| Glasgow Outcome Scale - Extended (GOS-E);mRS evaluation;NIHSS scores;Barthel Index evaluation;DTI/FA?;SWI;Softening oven volume;rate of complication; | — |
Countries
China
Contacts
Public ContactJin Hu
Huashan Hospital, Fudan University
Outcome results
None listed